Age Related Macular Degeneration - Pipeline Review - H2 2013





Published: October 2013 | Pages: 225 | Format: PDF

 Summary 

 Global Markets Direct’s, 'Age Related Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Age Related Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration. Age Related Macular Degeneration - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  A snapshot of the global therapeutic scenario for Age Related Macular Degeneration. 
  •  A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  •  Coverage of products based on various stages of development ranging from discovery till registration stages. 
  •  A feature on pipeline projects on the basis of monotherapy and combined therapeutics. 
  •  Coverage of the Age Related Macular Degeneration pipeline on the basis of route of administration and molecule type. 
  •  Key discontinued pipeline projects. 
  •  Latest news and deals relating to the products. 

 

 Reasons to buy 

 

  •  Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration. 
  •  Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  •  Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. 
  •  Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics. 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 

 

 Additional Information 

 Companies Mentioned 

 Alcon, Inc.  

 Johnson & Johnson  

 F. Hoffmann-La Roche Ltd.  

 Allergan, Inc.  

 Shionogi & Co., Ltd.  

 Lux Biosciences, Inc.  

 RetinaPharma Technologies, Inc.  

 Jeil Pharmaceutical Co., Ltd.  

 Merz GmbH & Co. KGaA  

 BioDiem Ltd  

 ReGenX Biosciences, LLC  

 OXiGENE, Inc.  

 Zenotech Laboratories Limited  

 NeoStem, Inc.  

 Progen Pharmaceuticals Limited  

 Hanall Pharmaceutical Co., Ltd.  

 ThromboGenics NV  

 e-Therapeutics plc  

 NanoCarrier Co., Ltd.  

 R-Tech Ueno, Ltd.  

 Intas Pharmaceuticals Ltd.  

 Paloma Pharmaceuticals, Inc.  

 Digna Biotech, S.L.  

 Ceregene, Inc.  

 StemCells, Inc.  

 Ora Bio Ltd.  

 Foamix Ltd.  

 Acucela Inc.  

 BioMAS Ltd.  

 Neovacs SA  

 Advanced Vision Therapies, Inc.  

 OcuCure Therapeutics, Inc.  

 Gene Signal International SA.  

 Promedior, Inc.  

 Ferrer Internacional S.A.  

 Indus Biotech Private Limited  

 Intellect Neurosciences, Inc.  

 Omeros Corporation  

 Angstrom Pharmaceuticals, Inc.  

 FirstString Research, Inc.  

 Stemedica Cell Technologies, Inc.  

 Cellceutix Corporation  

 Sirnaomics, Inc.  

 Resolvyx Pharmaceuticals, Inc  

 MacuCLEAR, Inc.  

 TRACON Pharmaceuticals, Inc.  

 Targa Therapeutics Corp.  

 SelectX Pharmaceuticals, Inc.  

 Neumedicines Inc.  

 Varinel, Inc. 

 Country 

 Global 

 Sector 

 Ophthalmology 

 Introduction 

 Global Markets Direct Report Coverage 

 Age Related Macular Degeneration Overview 

 Therapeutics Development 

 An Overview of Pipeline Products for Age Related Macular Degeneration 

 Age Related Macular Degeneration Therapeutics under Development by Companies 

 Age Related Macular Degeneration Therapeutics under Investigation by Universities/Institutes 

 Late Stage Products 

 Comparative Analysis 

 Mid Clinical Stage Products 

 Comparative Analysis 

 Early Clinical Stage Products 

 Comparative Analysis 

 Discovery and Pre-Clinical Stage Products 

 Comparative Analysis 

 Age Related Macular Degeneration Therapeutics - Products under Development by Companies 

 Age Related Macular Degeneration Therapeutics - Products under Investigation by Universities/Institutes 

 Companies Involved in Age Related Macular Degeneration Therapeutics Development 

 Alcon, Inc. 

 Johnson & Johnson 

 F. Hoffmann-La Roche Ltd. 

 Allergan, Inc. 

 Shionogi & Co., Ltd. 

 Lux Biosciences, Inc. 

 RetinaPharma Technologies, Inc. 

 Jeil Pharmaceutical Co., Ltd. 

 Merz GmbH & Co. KGaA 

 BioDiem Ltd 

 ReGenX Biosciences, LLC 

 OXiGENE, Inc. 

 Zenotech Laboratories Limited 

 NeoStem, Inc. 

 Progen Pharmaceuticals Limited 

 Hanall Pharmaceutical Co., Ltd. 

 ThromboGenics NV 

 e-Therapeutics plc 

 NanoCarrier Co., Ltd. 

 R-Tech Ueno, Ltd. 

 Intas Pharmaceuticals Ltd. 

 Paloma Pharmaceuticals, Inc. 

 Digna Biotech, S.L. 

 Ceregene, Inc. 

 StemCells, Inc. 

 Ora Bio Ltd. 

 Foamix Ltd. 

 Acucela Inc. 

 BioMAS Ltd. 

 Neovacs SA 

 Advanced Vision Therapies, Inc. 

 OcuCure Therapeutics, Inc. 

 Gene Signal International SA. 

 Promedior, Inc. 

 Ferrer Internacional S.A. 

 Indus Biotech Private Limited 

 Intellect Neurosciences, Inc. 

 Omeros Corporation 

 Angstrom Pharmaceuticals, Inc. 

 FirstString Research, Inc. 

 Stemedica Cell Technologies, Inc. 

 Cellceutix Corporation 

 Sirnaomics, Inc. 

 Resolvyx Pharmaceuticals, Inc 

 MacuCLEAR, Inc. 

 TRACON Pharmaceuticals, Inc. 

 Targa Therapeutics Corp. 

 SelectX Pharmaceuticals, Inc. 

 Neumedicines Inc. 

 Varinel, Inc. 

 Age Related Macular Degeneration - Therapeutics Assessment 

 Assessment by Monotherapy Products 

 Assessment by Route of Administration 

 Assessment by Molecule Type 

 Drug Profiles 

 volociximab - Drug Profile 

 ranibizumab - Drug Profile 

 PMX-20005 - Drug Profile 

 P-17 - Drug Profile 

 disitertide - Drug Profile 

 unoprostone isopropyl - Drug Profile 

 ocriplasmin - Drug Profile 

 PG-11047 - Drug Profile 

 CERE-140 - Drug Profile 

 TKI - Drug Profile 

 INDUS-815C - Drug Profile 

 ETX-6201 - Drug Profile 

 OMS-721 - Drug Profile 

 MC-1101 - Drug Profile 

 VEGF Kinoid - Drug Profile 

 RX-20001 - Drug Profile 

 OC-10X - Drug Profile 

 VAR-10200 - Drug Profile 

 A-6 - Drug Profile 

 aganirsen - Drug Profile 

 P-529 - Drug Profile 

 siRNA Micelle - Drug Profile 

 Peptide Vaccine - Drug Profile 

 TRC-105 - Drug Profile 

 AS-101 - Drug Profile 

 HL-036 - Drug Profile 

 INN-01 - Drug Profile 

 fosbretabulin disodium - Drug Profile 

 BDM-E - Drug Profile 

 RTU-007 - Drug Profile 

 KH-902 - Drug Profile 

 Retinylamine - Drug Profile 

 ORA-102 - Drug Profile 

 ETX-6991 - Drug Profile 

 Drug For Age Related Macular Degeneration - Drug Profile 

 CIGB-166 - Drug Profile 

 NMIL-121 - Drug Profile 

 LX-213 - Drug Profile 

 PRM-167 - Drug Profile 

 Drug For Ocular Diseases - Drug Profile 

 STP-601 - Drug Profile 

 VEGF/rGel - Drug Profile 

 Stem Cell Therapy For Macular Degeneration and Glaucoma - Drug Profile 

 MRZ-99030 - Drug Profile 

 S-646240 - Drug Profile 

 Lycium Anti-Angiogenic Proteoglycan - Drug Profile 

 Drug For Age-Related Macular Degeneration And Diabetic Retinopathy - Drug Profile 

 ARMD Program - Drug Profile 

 IN-N01-OX2 - Drug Profile 

 Anti-Angiogenic Compounds - Drug Profile 

 Cell Migration Inhibitors - Drug Profile 

 Metalloproteinase Inhibitors - Drug Profile 

 Age-Related Macular Degeneration Program - Drug Profile 

 Carnosic Acid - Drug Profile 

 Embryonic Stem Cells - Drug Profile 

 Neuregulins - Drug Profile 

 Asialo Triantennary Glycan - Drug Profile 

 Retinal Neuroprotective Compounds - Drug Profile 

 KN-014 - Drug Profile 

 Drug For Dry Age Related Macular Degeneration - Drug Profile 

 XB-2202 - Drug Profile 

 HMR-59 - Drug Profile 

 Stem Cell Therapy For Parkinson Disease And Age-related Macular Degeneration - Drug Profile 

 PRCN-408 - Drug Profile 

 Biosimilar For Age-Related Macular Degeneration - Drug Profile 

 FIB-111 - Drug Profile 

 CLG-561 - Drug Profile 

 Drug For AGMD - Drug Profile 

 MicroRNA-204 Mimic - Drug Profile 

 MicroRNA-211 Mimic - Drug Profile 

 ET-004 - Drug Profile 

 C16Y Peptide - Drug Profile 

 Age Related Macular Degeneration Therapeutics - Drug Profile Updates 

 Age Related Macular Degeneration Therapeutics - Discontinued Products 

 Age Related Macular Degeneration Therapeutics - Dormant Products 

 Age Related Macular Degeneration - Product Development Milestones 

 Featured News & Press Releases 

 Appendix 

 Methodology 

 Coverage 

 Secondary Research 

 Primary Research 

 Expert Panel Validation 

 Contact Us 

 Disclaimer 

 List of Tables 

 Number of Products Under Development for Age Related Macular Degeneration, H2 2013 

 Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2013 

 Number of Products under Development by Companies, H2 2013 

 Number of Products under Development by Companies, H2 2013 (Contd..1) 

 Number of Products under Development by Companies, H2 2013 (Contd..2) 

 Number of Products under Development by Companies, H2 2013 (Contd..3) 

 Number of Products under Investigation by Universities/Institutes, H2 2013 

 Comparative Analysis by Late Stage Development, H2 2013 

 Comparative Analysis by Mid Clinical Stage Development, H2 2013 

 Comparative Analysis by Early Clinical Stage Development, H2 2013 

 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Development by Companies, H2 2013 (Contd..1) 

 Products under Development by Companies, H2 2013 (Contd..2) 

 Products under Development by Companies, H2 2013 (Contd..3) 

 Products under Investigation by Universities/Institutes, H2 2013 

 Alcon, Inc., H2 2013 

 Johnson & Johnson, H2 2013 

 F. Hoffmann-La Roche Ltd., H2 2013 

 Allergan, Inc., H2 2013 

 Shionogi & Co., Ltd., H2 2013 

 Lux Biosciences, Inc., H2 2013 

 RetinaPharma Technologies, Inc., H2 2013 

 Jeil Pharmaceutical Co., Ltd., H2 2013 

 Merz GmbH & Co. KGaA, H2 2013 

 BioDiem Ltd, H2 2013 

 ReGenX Biosciences, LLC, H2 2013 

 OXiGENE, Inc., H2 2013 

 Zenotech Laboratories Limited, H2 2013 

 NeoStem, Inc., H2 2013 

 Progen Pharmaceuticals Limited, H2 2013 

 Hanall Pharmaceutical Co., Ltd., H2 2013 

 ThromboGenics NV, H2 2013 

 e-Therapeutics plc, H2 2013 

 NanoCarrier Co., Ltd., H2 2013 

 R-Tech Ueno, Ltd., H2 2013 

 Intas Pharmaceuticals Ltd., H2 2013 

 Paloma Pharmaceuticals, Inc., H2 2013 

 Digna Biotech, S.L., H2 2013 

 Ceregene, Inc., H2 2013 

 StemCells, Inc., H2 2013 

 Ora Bio Ltd., H2 2013 

 Foamix Ltd., H2 2013 

 Acucela Inc., H2 2013 

 BioMAS Ltd., H2 2013 

 Neovacs SA, H2 2013 

 Advanced Vision Therapies, Inc., H2 2013 

 OcuCure Therapeutics, Inc., H2 2013 

 Gene Signal International SA., H2 2013 

 Promedior, Inc., H2 2013 

 Ferrer Internacional S.A., H2 2013 

 Indus Biotech Private Limited, H2 2013 

 Intellect Neurosciences, Inc., H2 2013 

 Omeros Corporation, H2 2013 

 Angstrom Pharmaceuticals, Inc., H2 2013 

 FirstString Research, Inc., H2 2013 

 Stemedica Cell Technologies, Inc., H2 2013 

 Cellceutix Corporation, H2 2013 

 Sirnaomics, Inc., H2 2013 

 Resolvyx Pharmaceuticals, Inc, H2 2013 

 MacuCLEAR, Inc., H2 2013 

 TRACON Pharmaceuticals, Inc., H2 2013 

 Targa Therapeutics Corp., H2 2013 

 SelectX Pharmaceuticals, Inc., H2 2013 

 Neumedicines Inc., H2 2013 

 Varinel, Inc., H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013 

 Age Related Macular Degeneration Therapeutics - Drug Profile Updates 

 Age Related Macular Degeneration Therapeutics - Discontinued Products 

 Age Related Macular Degeneration Therapeutics - Dormant Products 

 Age Related Macular Degeneration Therapeutics - Dormant Products (Contd..1) 

 Age Related Macular Degeneration Therapeutics - Dormant Products (Contd..2) 

 List of Figures 

 Number of Products under Development for Age Related Macular Degeneration, H2 2013 

 Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Investigation by Universities/Institutes, H2 2013 

 Late Stage Products, H2 2013 

 Mid Clinical Stage Products, H2 2013 

 Early Clinical Stage Products, H2 2013 

 Discovery and Pre-Clinical Stage Products, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Route of Administration, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Molecule Type, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013